Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSA | P10619 | 9/20 | 0.48 |
| ▸ | DCAF1 | Q9Y4B6 | 1/20 | 0.47 |
| ▸ | TMPRSS4 | Q9NRS4 | 2/20 | 0.44 |
| ▸ | CYP26A1 | O43174 | 3/20 | 0.44 |
| ▸ | P2RX1 | P51575 | 1/20 | 0.43 |
| ▸ | P2RX4 | Q99571 | 1/20 | 0.43 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.43 |
| ▸ | EEF2K | O00418 | 1/20 | 0.41 |
| ▸ | UTS2R | Q9UKP6 | 1/20 | 0.41 |
| ▸ | FFAR1 | O14842 | 3/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6097139 | 1.00 | CTSA (0.48) | CTSADCAF1TMPRSS4CYP26A1P2RX1 | |
| SCHEMBL5927615 | 0.93 | CTSA (0.47) | CTSADCAF1TMPRSS4P2RX1P2RX4 | |
| SCHEMBL4827815 | 0.90 | DCAF1 (0.54) | CTSADCAF1CYP26A1 | |
| SCHEMBL5926628 | 0.90 | DCAF1 (0.43) | CTSADCAF1TMPRSS4P2RX1P2RX4 | |
| SCHEMBL5926547 | 0.90 | DCAF1 (0.43) | CTSADCAF1TMPRSS4P2RX1P2RX4 | |
| SCHEMBL6099049 | 0.89 | CTSA (0.50) | CTSACYP26A1EEF2KFFAR1 | |
| SCHEMBL5927170 | 0.89 | UTS2R (0.52) | CTSADCAF1EEF2KUTS2R | |
| SCHEMBL5927207 | 0.87 | CTSA (0.53) | CTSACYP26A1EEF2KFFAR1 | |
| SCHEMBL6097767 | 0.86 | CTSA (0.51) | CTSAEEF2KFFAR1 | |
| SCHEMBL6100609 | 0.85 | MMP12 (0.48) | CTSADCAF1P2RX1FFAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7544699-B2 | Aryl and heteroaryl compounds, compositions, and methods of use | TRANSTECH PHARMA, INC. (US) | 2009-06-09 | — | — | US | disclosed |
| EP-1660439-A2 | ARYL AND HETEROARYL COMPOUNDS, COMPOSITIONS, AND METHODS OF USE | Transtech Pharma, Inc. (US) | 2006-05-31 | — | — | EP | disclosed |
| US-20050059705-A1 | Aryl and heteroaryl compounds, compositions, and methods of use | VTVX HOLDINGS I LLC | 2005-03-17 | — | — | US | disclosed |
| WO-2005014533-A2 | ARYL AND HETEROARYL COMPOUNDS, COMPOSITIONS, AND METHODS OF USE | TRANSTECH PHARMA, INC. (US) | 2005-02-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050059705-A1 | Aryl and heteroaryl compounds, compositions, and methods of use | TFPI, F3, F2 | CTSA 465/4885DCAF1 3885/4885TMPRSS4 1269/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.